Pikkelysömör: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• IL-17 12
• IL-23 6
• STAT3 0
• TNF 5
• JAK 1
• GLP-1 5
• TYK2 1
• PI3K 0
• NLRP3 0
• IL-6 0
• IL-1 0
• AKT 0
• MAPK 0
• PDE4 1
• NRF2 0
• PD-1 0
• PPAR 0
• STING 0
• mTOR 0
• TLR4 0
• AMPK 0
• ERK 0
• GIP 1
• VEGF 0
• MMP-9 0
• PD-L1 0
• COX-2 0
• HIF-1 0
• IL-4 0
• SIRT1 0
• TP53 0
• APOE 0
• CGRP 0
• IL-13 0
• KEAP1 0
• LAG-3 0
• PCSK9 0
• PKM2 0
• SGLT2 0
• TSLP 0
• AR 0
• BCL-2 0
• BDNF 0
• BRD4 0
• CD123 0
• CD19 0
• CD40 0
• CSF1R 0
• CTLA-4 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• EZH2 0
• FTO 0
• G6PD 0
• GPRC5D 0
• HMGB1 0
• HSP90 0
• IDH 0
• JNK 0

10+ intézményből 10, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Synergistic Nano-Therapeutic Approach for Psoriasis: Targeting TNF-α and IL-17 Pathways via Transdermal Delivery (SKINNOVATE)

  Academisch Ziekenhuis Groningen· Groningen, Hollandia· EU contribution 232 916 EUR· until 2027. okt.

• European Commission (Horizon Europe) · HORIZON-ERC

  Unmasking Non-Genetic Determinants Instructing Tumor Initiation (IGNITE)

  Fundacio Institut de Recerca Biomedica (Irb Barcelona)· Barcelona, Spanyolország· EU contribution 1 995 000 EUR· until 2030. szept.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Positive allosteric modulators of the PD-1•PD-L1 interaction as a new mode of therapeutic intervention for autoimmune diseases: preclinical proof of concept in humanized mice (PAMinMICE)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 150 000 EUR· until 2027. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Dissolving microneedle array patch-based psoriatic immunotherapy using nanoparticles (MAPiT)

  Stockholms Universitet· Stockholm, Svédország· EU contribution 222 728 EUR· until 2027. febr.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification (Lab-In-Skin)

  Universiteit Twente· Enschede, Hollandia· EU contribution 150 000 EUR· until 2026. dec.

  The disease is named only in the funder's project summary, not in the title.

5 of 9 running projects, newest first. Listed amounts together: 31,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis

  NCT06380907· Zai Lab (Hong Kong), Ltd.· Frissítve: 2026. aug. 10.

  “Sponsor decision”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 28
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 4
• Gene Expression Profiling 66
• Sequence Analysis, RNA 6
• Exome Sequencing 5
• Proteomics 24
• Metabolomics 13
• Flow Cytometry 11
• Immunohistochemistry 24
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 23
• Machine Learning 27
• Deep Learning 4
• Cohort Studies 63
• Genome-Wide Association Study 38

• Identification of plaque psoriasis subgroups based on peripheral blood immune cells subtypes and their relationship with biologic therapy efficacy: a single-center longitudinal cohort study in China.

  Expert Opin Biol Ther, 2026. jún.

• RA and PsA synovial tissue single-cell analysis demonstrates differential fibroblast populations with distinct phenotypes and functional capacities.

  Ann Rheum Dis, 2026. ápr.

• The Level and Clinical Significance of B Lymphocytes and Immune Molecules (IL-4, IL-10, BAFF, and IgD) in Psoriasis.

  Immun Inflamm Dis, 2026. márc.

• Single cell mapping identifies a distinct platelet-phenotype in psoriatic type III inflammation.

  Nat Commun, 2025. dec.

• CD3+ immune cell endotypes are associated with PsA disease phenotype and response to advanced therapy: an integrated mass cytometry and proteomics cohort study.

  Ann Rheum Dis, 2025. nov.

• Cigarette and Cannabis Smoking Effects on GPR15+ Helper T Cell Levels in Peripheral Blood: Relationships with Epigenetic Biomarkers.

  Genes (Basel), 2020. jan.

• Distinctive downmodulation of plasmacytoid dendritic cell functions by vitamin D3 analogue calcipotriol.

  J Dermatol Sci, 2016. jún.

• A left/right comparison of twice-daily calcipotriol ointment and calcitriol ointment in patients with psoriasis: the effect on keratinocyte subpopulations.

  Acta Derm Venereol, 2004. jan.

• Reduction of epidermal abnormalities and inflammatory changes in psoriatic plaques during treatment with vitamin D3 analogs.

  J Investig Dermatol Symp Proc, 1996. ápr.

• Calcitriol and its analog KH 1060 induce similar changes in keratinocyte cell cycle progression after topical application to mouse skin. A bromodeoxyuridine pulse-chase flow cytometric study.

  J Investig Dermatol Symp Proc, 1996. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.